Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Savara (NASDAQ:SVRA) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $8.00 price target on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 147.68% from the company’s current price.

A number of other research analysts have also recently weighed in on the company. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday. Finally, HC Wainwright reduced their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.86.

Savara Trading Up 7.0 %

SVRA opened at $3.23 on Friday. The company’s 50-day moving average is $3.48 and its 200 day moving average is $3.99. Savara has a fifty-two week low of $2.82 and a fifty-two week high of $5.70. The firm has a market capitalization of $554.33 million, a PE ratio of -7.51 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). As a group, research analysts predict that Savara will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This represents a 10.48 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Choreo LLC acquired a new position in Savara during the second quarter worth $59,000. DRW Securities LLC purchased a new stake in shares of Savara during the second quarter worth about $62,000. Virtu Financial LLC acquired a new position in shares of Savara during the 3rd quarter worth about $67,000. Principal Financial Group Inc. lifted its stake in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after buying an additional 6,973 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after acquiring an additional 18,534 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.